[1] |
Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019; 70, 531−44. doi: 10.1016/j.jhep.2018.10.033 |
[2] |
Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med, 2018; 18, 245−50. |
[3] |
George J, Anstee Q, Ratziu V, et al. NAFLD: The evolving landscape. J Hepatol, 2018; 68, 227−9. doi: 10.1016/j.jhep.2017.11.016 |
[4] |
Li J, Zou BY, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019; 4, 389−98. doi: 10.1016/S2468-1253(19)30039-1 |
[5] |
Khan RS, Bril F, Cusi K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology, 2019; 70, 711−24. |
[6] |
Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int, 2016; 36, 275−83. doi: 10.1111/liv.12912 |
[7] |
Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol, 2021; 110, 921−37. doi: 10.1007/s00392-020-01709-7 |
[8] |
Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci, 2016; 17, 562. doi: 10.3390/ijms17040562 |
[9] |
Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab, 2020; 42, 101092. doi: 10.1016/j.molmet.2020.101092 |
[10] |
Ren XX, Chen ZA, Zheng S, et al. Association between triglyceride to HDL-C Ratio (TG/HDL-C) and insulin resistance in Chinese patients with newly diagnosed type 2 diabetes mellitus. PLoS One, 2016; 11, e0154345. doi: 10.1371/journal.pone.0154345 |
[11] |
Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev, 2019; 40, 1367−93. doi: 10.1210/er.2019-00034 |
[12] |
Nemes K, Åberg F. Interpreting lipoproteins in nonalcoholic fatty liver disease. Curr Opin Lipidol, 2017; 28, 355−60. doi: 10.1097/MOL.0000000000000427 |
[13] |
Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol, 2016; 10, 420−5.e1. doi: 10.1016/j.jacl.2015.12.026 |
[14] |
DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013; 227, 429−36. doi: 10.1016/j.atherosclerosis.2013.01.022 |
[15] |
Ma ZM, Xu CN, Kang XP, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med, 2020; 18, 133. doi: 10.1186/s12967-020-02296-x |
[16] |
Jaruvongvanich V, Ahuja W, Wirunsawanya K, et al. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2017; 29, 1031−5. doi: 10.1097/MEG.0000000000000931 |
[17] |
Wei FJ, Li JX, Chen C, et al. Higher serum uric acid level predicts non-alcoholic fatty liver disease: A 4-year prospective cohort study. Front Endocrinol, 2020; 11, 179. doi: 10.3389/fendo.2020.00179 |
[18] |
Zheng XY, Gong LL, Luo R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis, 2017; 16, 202. doi: 10.1186/s12944-017-0531-5 |
[19] |
Liu CQ, He CM, Chen N, et al. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep, 2016; 6, 38605. doi: 10.1038/srep38605 |
[20] |
Kocak MZ, Aktas G, Erkus E, et al. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992), 2019; 65, 9−15. doi: 10.1590/1806-9282.65.1.9 |
[21] |
Aktas G, Kocak MZ, Bilgin S, et al. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male, 2020; 23, 1098−102. doi: 10.1080/13685538.2019.1678126 |
[22] |
Kurtkulagi O, Tel BMA, Kahveci G, et al. Hashimoto's thyroiditis is associated with elevated serum uric acid to high density lipoprotein-cholesterol ratio. Rom J Intern Med, 2021; 59, 403−8. |
[23] |
Aktas G, Khalid A, Kurtkulagi O, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med, 2022; 134, 297−302. doi: 10.1080/00325481.2022.2039007 |
[24] |
Zhang YN, Wang QQ, Chen YS, et al. Association between serum uric acid to HDL-cholesterol ratio and nonalcoholic fatty liver disease in lean Chinese adults. Int J Endocrinol, 2020; 2020, 5953461. |
[25] |
Gao X, Fan JG, Study Group of Liver and Metabolism, et al. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes, 2013; 5, 406−15. doi: 10.1111/1753-0407.12056 |
[26] |
Petersmann A, Nauck M, Müller-Wieland D, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes, 2018; 126, 406−10. doi: 10.1055/a-0584-6223 |
[27] |
Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol, 2019; 16, 182−241. |
[28] |
Xu CF. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back. Hepatol Int, 2016; 10, 286−93. doi: 10.1007/s12072-015-9682-5 |
[29] |
Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A meta-analysis. Acta Med Indones, 2017; 49, 136−47. |
[30] |
Liu ZT, Que SP, Zhou L, et al. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: A meta-analysis of prospective studies. Sci Rep, 2015; 5, 14325. doi: 10.1038/srep14325 |
[31] |
Zhou YJ, Wei FF, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem, 2016; 49, 636−42. doi: 10.1016/j.clinbiochem.2015.12.010 |
[32] |
Maylor BD, Zakrzewski-Fruer JK, Orton CJ, et al. Beneficial postprandial lipaemic effects of interrupting sedentary time with high-intensity physical activity versus a continuous moderate-intensity physical activity bout: A randomised crossover trial. J Sci Med Sport, 2018; 21, 1250−5. doi: 10.1016/j.jsams.2018.05.022 |
[33] |
Chen HY, Li SC, Chen LF, et al. The effects of cigarette smoking and smoking cessation on high-density lipoprotein functions: implications for coronary artery disease. Ann Clin Biochem, 2019; 56, 100−11. doi: 10.1177/0004563218788386 |
[34] |
Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. Int J Mol Sci, 2020; 21, 8985. doi: 10.3390/ijms21238985 |
[35] |
Waldman B, Jenkins AJ, Davis TME, et al. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care, 2014; 37, 2351−8. doi: 10.2337/dc13-2738 |
[36] |
Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol, 2015; 3, 78−84. doi: 10.14218/JCTH.2014.00037 |
[37] |
Du TT, Sun XX, Yuan G, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism, 2016; 65, 1391−8. doi: 10.1016/j.metabol.2016.06.006 |
[38] |
Kosekli MA, Kurtkulagii O, Kahveci G, et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study. Rev Assoc Med Bras (1992), 2021; 67, 549−54. doi: 10.1590/1806-9282.20201005 |
[39] |
Sun DQ, Wu SJ, Liu WY, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets, 2016; 20, 375−87. doi: 10.1517/14728222.2016.1096930 |
[40] |
Arrese M, Cabrera D, Kalergis AM, et al. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci, 2016; 61, 1294−303. doi: 10.1007/s10620-016-4049-x |